VolitionRx Participates in Launch of DETECSEPS Program in France

PartnershipNu.Q® NETs AssayPositive

AI Analysis

Summary

VolitionRx's Nu.Q® NETs Assay has been selected as the sole biomarker for the French government-funded DETECSEPS program, a €6.3 million consortium for real-world evaluation of early sepsis detection. This represents a validation of the company's diagnostic technology in a major European healthcare initiative.

Outcome Details

Selected as sole biomarker for French government-funded DETECSEPS program for real-world evaluation of early sepsis detection

Importance:6/10

Sentiment:

0.70

partnershipdiagnosticgovernment-fundedsepsis detectionreal-world evaluationFrance

Related Companies

$VNRX

Read the original article

Published by PR Newswire Biotech on September 17, 2026 12:17 PM

Read Original